Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02340221
Title	A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)
Acronym	SANDPIPER
Recruitment	Terminated
Gender	female
Phase	Phase III
Variant Requirements	Yes
Sponsors	Hoffmann-La Roche
Indications	estrogen-receptor positive breast cancer
Therapies	Fulvestrant + Taselisib Fulvestrant
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| GRC \| FRA \| FIN \| ESP \| DEU \| CZE \| CAN \| BGR \| AUT \| AUS